Items Tagged ‘MET exon 14 alterations’

June 5, 2018

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations


The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine […]

View full entry

Tags: crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, MET exon 14 alterations, News, non-small cell lung cancer, nsclc, treatment, xalkori